1. Home
  2. SEED vs APRE Comparison

SEED vs APRE Comparison

Compare SEED & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

HOLD

Current Price

$1.06

Market Cap

12.1M

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.82

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEED
APRE
Founded
1997
2006
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
11.5M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
SEED
APRE
Price
$1.06
$0.82
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
27.4K
116.3K
Earning Date
01-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.55
52 Week High
$2.49
$2.22

Technical Indicators

Market Signals
Indicator
SEED
APRE
Relative Strength Index (RSI) 41.41 51.91
Support Level $1.00 $0.75
Resistance Level $1.47 $0.98
Average True Range (ATR) 0.06 0.07
MACD 0.00 0.01
Stochastic Oscillator 31.83 82.90

Price Performance

Historical Comparison
SEED
APRE

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: